S757
Clinical - Lung
ESTRO 2026
Fifty-seven patients (58.7%) received consolidation ICIs.The survival outcomes were promising:The median PFS was 20.2 months.The median OS was not reached (NR) at the time of data cutoff.The 1-year PFS and OS rates were 69.0% and 89.7%, respectively.The ORR was 84.5%.Exploratory analyses indicated that the administration of consolidation immunotherapy was associated with improvements in both PFS and OS.Clinical T stage was identified as a significant independent prognostic factor for OS.The treatment regimen demonstrated a manageable safety profile, with a grade ≥ 3 pneumonitis incidence of 8.2%. Conclusion: The multimodal strategy incorporating induction chemoimmunotherapy followed by definitive radiotherapy, with or without consolidation immunotherapy, demonstrates promising efficacy and an acceptable safety profile in patients with unresectable stage III-IVA NSCLC. The survival outcomes, including a median PFS of 20.2 months and a promising 1-year OS rate, compare favorably with historical data. These results suggest that forward- shifting immunotherapy to the induction phase may represent a viable strategy to improve outcomes. Further prospective, randomized controlled trials are warranted to validate these findings and define the optimal patient population for this intensive treatment approach, given the retrospective nature and limited sample size. References: no references Keywords: Induction Immunochemotherapy, NSCLC End-to-end genomic test turnaround times in non- small cell lung cancer across NHS hospitals in the East of England Emily CS Scott 1,2 , Sarah Bodsworth 3 , Jo Lowry 4 , Emmanuel Ncube 4 , Richard Sandford 4 , Peter J Hoskin 1,2 1 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 2 ., East of England Cancer Alliance, Cambridge, United Kingdom. 3 Data and Performance Improvement, East of England Cancer Alliance, Cambridge, United Kingdom. 4 ., East Genomic Medicine Service Alliance, Cambridge, United Kingdom Purpose/Objective: Access to timely genomic results is essential for precision oncology in non-small cell lung cancer (NSCLC), where treatment selection depends on predictive biomarkers. National policy in England recommends biomarker genomic testing at diagnosis and complete end-to-end turnaround times (TATs) within 14 days from sample acquisition to the final Digital Poster 569
malignancies: extended abstract. Mediastinum. 2024;8:25. Published 2024 May 29. doi:10.21037/med- 24-10 3. Miller ED, Wu T, McKinley G, et al. Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following Radiotherapy. Int J Radiat Oncol Biol Phys. 2024;118(1):124-136. 4. Finnegan RN, Chin V, Chlap P, et al. Open-source, fully-automated hybrid cardiac substructure segmentation: development and optimisation. Phys Eng Sci Med. 2023;46(1):377-393. Keywords: Thymoma, Cardiac Adverse Events, PORT Induction Immunochemotherapy Followed by Definitive Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Observational Study YANG JIU, QIFENG WANG, YANG WEI Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China Purpose/Objective: The PACIFIC regimen established consolidation immunotherapy after chemoradiotherapy as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, its efficacy appears attenuated in patients with a higher tumor burden (e.g., stage IIIB-IIIC), as suggested by trials like Digital Poster 366 GEMSTONE-301. This observation underscores the persistent unmet need for more effective therapeutic strategies in locally advanced NSCLC. This study investigates the real-world efficacy and safety of
intensifying treatment by forward-shifting immunotherapy to the induction phase. Material/Methods: We retrospectively reviewed patients with
histologically or cytologically confirmed stage III-IVA unresectable NSCLC who received treatment at Sichuan Cancer Hospital between January 2022 and August 2024. Patients received induction immune checkpoint inhibitors (ICIs) combined with chemotherapy followed by definitive radiotherapy, with or without subsequent consolidation immunotherapy. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were the objective response rate (ORR) and the safety profile, with adverse events graded according to CTCAE v5.0 criteria. Survival analysis was performed using the Kaplan-Meier method. Results: A total of 97 patients were included in the final analysis. The median follow-up time from the initiation of induction therapy was 18.1 months. The study population comprised 13.4% stage IIIA, 47.4% stage IIIB, 27.8% stage IIIC, and 11.3% stage IVA patients.
Made with FlippingBook - Share PDF online